- Home
- OCG vs UNCY Comparison
OCG vs UNCY Comparison
Compare OCG & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCG
- UNCY
- Stock Information
- Founded
- OCG 2018
- UNCY 2016
- Country
- OCG Hong Kong
- UNCY United States
- Employees
- OCG N/A
- UNCY N/A
- Industry
- OCG Other Consumer Services
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- OCG Consumer Discretionary
- UNCY Health Care
- Exchange
- OCG Nasdaq
- UNCY Nasdaq
- Market Cap
- OCG 81.7M
- UNCY 74.2M
- IPO Year
- OCG 2020
- UNCY 2021
- Fundamental
- Price
- OCG $3.96
- UNCY $3.87
- Analyst Decision
- OCG
- UNCY Strong Buy
- Analyst Count
- OCG 0
- UNCY 4
- Target Price
- OCG N/A
- UNCY $63.75
- AVG Volume (30 Days)
- OCG 95.8K
- UNCY 527.4K
- Earning Date
- OCG 11-11-2025
- UNCY 11-12-2025
- Dividend Yield
- OCG N/A
- UNCY N/A
- EPS Growth
- OCG N/A
- UNCY N/A
- EPS
- OCG N/A
- UNCY N/A
- Revenue
- OCG $622,690.00
- UNCY N/A
- Revenue This Year
- OCG N/A
- UNCY N/A
- Revenue Next Year
- OCG N/A
- UNCY $3,131.28
- P/E Ratio
- OCG N/A
- UNCY N/A
- Revenue Growth
- OCG N/A
- UNCY N/A
- 52 Week Low
- OCG $1.01
- UNCY $3.40
- 52 Week High
- OCG $7.47
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- OCG 48.47
- UNCY 34.49
- Support Level
- OCG $3.70
- UNCY $4.23
- Resistance Level
- OCG $4.18
- UNCY $4.43
- Average True Range (ATR)
- OCG 0.52
- UNCY 0.20
- MACD
- OCG 0.10
- UNCY -0.00
- Stochastic Oscillator
- OCG 76.58
- UNCY 8.20
About OCG Oriental Culture Holding LTD
Oriental Culture Holding Ltd is an online provider of collectibles and artwork e-commerce services. The company also offers online and offline integrated marketing, storage, and technical maintenance services to customers. The company operates through one segment, namely, e-commerce of artwork trading. It generates revenue through listing service fees, transaction fees, and other revenues collected from traders.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.